Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00670319 · ClinicalTrials.gov registry record · Phase 3
Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 7,705
- Enrollment target
NCT00670319: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT00670319 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 7,705 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (899% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00670319, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7,705 participants
- Enrollment target
Study Summary
To study the effect of long-term treatment with raloxifene, compared with placebo, on the rate of new vertebral fractures in osteoporotic postmenopausal women with and without existing vertebral fractures.
Interventions
- DRUG Placebo
- DRUG Raloxifene HCL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,705 participants |
| Start Date | 1994-11 |
| Est. Completion | 1999-09 |
| Phase | Phase 3 |
What the finished NCT00670319 record still lists
NCT00670319 is an interventional study that assigns participants to a tested intervention. Its 7,705 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (899% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00670319 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00670319 about?
NCT00670319 is a clinical study titled "Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis". To study the effect of long-term treatment with raloxifene, compared with placebo, on the rate of new vertebral fractures in osteoporotic postmenopausal women with and without existing vertebral fractures.
What is the current status of trial NCT00670319?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,705 participants. The study started on 1994-11. Estimated completion is 1999-09.
What interventions are being tested in trial NCT00670319?
The interventions under investigation include: Placebo (DRUG), Raloxifene HCL (DRUG).
Who is sponsoring clinical trial NCT00670319?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00670319's enrollment target sits among peer trials
7,705 33rd of 2000 higher than 1,968 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06560398 · 7,649 participants · NA
Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S)
- NCT03848312 · 7,600 participants · Phase 3
Preventing Alzheimer's With Cognitive Training
- NCT00439049 · 7,500 participants
Substance Abuse Pre-Treatment Screening Study
- NCT04809740 · 7,500 participants · NA
Evaluating the Implementation and Impact of Navigator-delivered ePRO System
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia